Biodexa Pharmaceuticals (BDRX) Total Liabilities (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Total Liabilities across 13 years of filings, most recently posting $9.0 million for Q4 2025.

• In Q4 2025, Total Liabilities rose 8.71% year-over-year to $9.0 million; the TTM figure through Dec 2025 stood at $9.0 million (up 8.71% YoY), while the FY2025 annual figure was $8.9 million, up 8.19% from the prior year.
• Total Liabilities came in at $9.0 million for Q4 2025 at Biodexa Pharmaceuticals, up from $4.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $9.0 million in Q4 2025 to a low of $2.8 million in Q2 2022.
• Average Total Liabilities over 5 years is $5.4 million, with a median of $5.4 million recorded in 2021.
• Year-over-year, Total Liabilities tumbled 56.36% in 2022 and surged 162.59% in 2023.
• Over 5 years, Total Liabilities stood at $3.3 million in 2021, then fell by 16.45% to $2.8 million in 2022, then surged by 162.59% to $7.3 million in 2023, then gained by 13.89% to $8.3 million in 2024, then gained by 8.71% to $9.0 million in 2025.
• Per Business Quant data, the three most recent Total Liabilities figures were $9.0 million in Q4 2025, $4.5 million in Q2 2025, and $8.3 million in Q4 2024.